Frontiers in hemodialysis: Innovations and technological advances.
bioartificial kidney
convection
expanded hemodialysis
graphene oxide membrane
hemodialysis
incremental
medium cut-off membrane
mixed matrix membrane
online hemodiafiltration
wearable artificial kidney
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
26
03
2020
revised:
30
07
2020
accepted:
03
08
2020
pubmed:
12
8
2020
medline:
9
3
2021
entrez:
12
8
2020
Statut:
ppublish
Résumé
As increasing demand for hemodialysis (HD) treatment incurs significant financial burden to healthcare systems and ecological burden as well, novel therapeutic approaches as well as innovations and technological advances are being sought that could lead to the development of purification devices such as dialyzers with improved characteristics and wearable technology. Novel knowledge such as the development of more accurate kinetic models, the development of novel HD membranes with the use of nanotechnology, novel manufacturing processes, and the latest technology in the science of materials have enabled novel solutions already marketed or on the verge of becoming commercially available. This collaborative article reviews the latest advances in HD as they were presented by the authors in a recent symposium titled "Frontiers in Haemodialysis," held on 12th December 2019 at the Royal Society of Medicine in London.
Substances chimiques
Membranes, Artificial
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-182Informations de copyright
© 2020 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.
Références
Malchesky PS. Renal support: a time to reassess the direction!. Artif Organs. 2019;43:615-617.
Saran R, Robinson B, Abbott KC, et al. United States Renal Data System. 2019 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;S0272-6386(19)31009-1. https://doi.org/10.1053/j.ajkd.2019.09.003
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709-33.
Wieringa FP, Sheldon M. The Kidney Health Initiative innovation roadmap for renal replacement therapies: building the yellow brick road, while updating the map. Artif Organs. 2020;44:111-22.
Ronco C, Clark WR. Haemodialysis membranes. Nat Rev Nephrol. 2018;14:394-410.
Daugirdas JT, Greene T, Rocco MV, Kaysen GA, Depner TA, Levin NW, et al. Effect of frequent hemodialysis on residual kidney function. Kidney Int. 2013;83:949-58.
NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis. 1997;30 Suppl 2:S67-136.
Sandrini M, Vizzardi V, Valerio F, Ravera S, Manili L, Zubani R, et al. Incremental peritoneal dialysis: a 10 year single-centre experience. J Nephrol. 2016;29:871-9.
Basile C, Casino FG, Kalantar-Zadeh K. Is incremental hemodialysis ready to return on the scene? From empiricism to kinetic modelling. J Nephrol. 2017;30:521-9.
Casino FG, Basile C. The variable target model: a paradigm shift in the incremental HD prescription. Nephrol Dial Transplant. 2017;32:182-90.
National Kidney Foundation. KDOQI clinical practice guidelines for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66:884-930.
Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant. 1996;11:1574-81.
Casino FG, Basile C. A user-friendly tool for incremental HD prescription. Nephrol Dial Transplant. 2018;33:1046-53.
Basile C, Casino FG, on behalf of the EUDIAL Working Group of ERA- EDTA. Incremental HD and residual kidney function: more and more observations but no trials. Nephrol Dial Transplant. 2019;34:1806-11.
European Best Practice Guidelines II. 3 HD dose and residual renal function (Kr). Nephrol Dial Transplant. 2002;17 Suppl 7:S24.
Deira J, Suárez MA, López F, García-Cabrera E, Gascón A, Torregrosa E., et al. IHDIP: a controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients. BMC Nephrol. 2019;20:8. https://doi.org/10.1186/s12882-018-1189-6
Mahomed FA. On the pathology of uraemia and the so called uraemic convulsion. Br Med J. 1877;2:10-12.
Saran R, Canaud BJ, Depner TA, Keen ML, McCullough KP, Marshall MR, et al. Dose of dialysis: key lessons from major observational studies and clinical trials. Am J Kidney Dis. 2004;44(5 Suppl 2):47-53.
Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-43.
Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013;24:487-97.
Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012;23:1087-96.
Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013;28:192-202.
Peters SA, Bots ML, Canaud B, Davenport A, Grooteman MP, Kircelli F, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant. 2016;31:978-84.
Marcelli D, Scholz C, Ponce P, Sousa T, Kopperschmidt P, Grassmann A, et al. High-volume postdilution hemodiafiltration is a feasible option in routine clinical practice. Artif Organs. 2015;39:142-9.
Willy K, Hulko M, Storr M, Speidel R, Gauss J, Schindler R, et al. In vitro dialysis of cytokine-rich plasma with high and medium cut-off membranes reduces its procalcific activity. Artif Organs. 2017;41:803-9.
Maduell F, Rodas L, Broseta JJ, Gómez M, Xipell Font M, Molina A, et al. High-permeability alternatives to current dialyzers performing both high-flux hemodialysis and postdilution online hemodiafiltration. Artif Organs. 2019;43:1014-21.
Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int. 1999;56:2005-15.
Kidambi PR, Jang D, Idrobo JC, Boutilier MSH, Wang L, Kong J, et al. Nanoporous atomically thin graphne membranes for desalting and dialysis applications. Adv Mater. 2017;29:1700277.
Joshi RK, Carbone P, Wang FC, Kravets VG, Su Y, Grigorieva IV, et al. Precise and ultrafast molecular sieving through graphene oxide membranes. Science. 2014;343:752-4.
Georgakilas V, Tiwari JN, Kemp KC, Perman JA, Bourlinos AB, Kim KS, et al. Noncovalent functionalization of graphene and graphene oxide for energy materials, biosensing, catalytic, and biomedical applications. Chem Rev. 2016;116:5464-519.
Ronco C, Bowry S. Nanoscale modulation of the pore dimensions, size distribution and structure of a new polysulfone-based high-flux dialysis membrane. Int J Artif Organs. 2001;24:726-35.
Song JH, Yu HW, Ham MH, Kim IS. Tunable ion sieving of graphene membranes through the control of nitrogen-bonding configuration. Nano Lett. 2018;18:5506-13.
Abraham J, Vasu KS, Williams CD, Gopinadhan K, Su Y, Cherian CT, et al. Tunable sieving of ions using graphene oxide membranes. Nat Nanotech. 2017;12:546-50.
Zhou KG, Vasu KS, Cherian CT, Neek-Amal M, Zhang JC, Ghorbanfekr-Kalashami H, et al. Electrically controlled water permeation through graphene oxide membranes. Nature. 2018;559:236-40.
Martin C, Kostarelos K, Prato M, Bianco A. Biocompatibility and biodegradability of 2D materials: graphene and beyond. Chem Commun. 2019;55:5540-6.
Kurapati R, Bonachera F, Russier J, Sureshbabu AR, Ménard-Moyon C, Kostarelos K, et al. Covalent chemical functionalization enhances the biodegradation of graphene oxide. 2D Mater. 2018;5:e015020.
Pavlenko D, van Geffen E, van Steenbergen MJ, Glorieux G, Vanholder R, Gerritsen KGF, et al. New lowflux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. Sci Rep. 2016;6:34429.
Geremia I, Bansal R, Stamatialis D. In vitro assessment of mixed matrix hemodialysis membrane for achieving endotoxin-free dialysate combined with high removal of uremic toxins from human plasma. Acta Biomater. 2019;90:100-11.
Aebischer P, Ip TK, Panol G, Galletti PM. The bioartificial kidney: progress towards an ultrafiltration device with renal epithelial cells processing. Life Support Syst. 1987;5:159-68.
Nikolovski J, Gulari E, Humes HD. Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant. 1999;8:351-64.
Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol. 2008;19:1034-40.
Schophuizen CMS, De Napoli IE, Jansen J, Teixeira S, Wilmer MJ, Hoenderop JGJ, et al. Development of a living membrane comprising a functional human renal proximal tubule cell monolayer on polyethersulfone polymeric membrane. Acta Biomater. 2015;14:22-32.
Legallais C, Kim D, Mihaila SM, Mihajlovic M, Figliuzzi M, Bonandrini B, et al. Bioengineering organs for blood detoxification. Adv Healthc Mater. 2018;7:e1800430.
Chevtchik NV, Fedecostante M, Jansen J, Mihajlovic M, Wilmer M, Rüth M, et al. Upscaling of a living membrane for bioartificial kidney device. Eur J Pharmacol. 2016;790:28-35.
Wieringa FP, Sheldon MI, Hidalgo-Simon A. Regulatory approaches to stimulate innovative renal replacement therapies. Nat Rev Nephrol. 2020. https://doi.org/10.1038/s41581-020-0275-8
Davenport A, Gura V, Ronco C, Beizai M, Ezon C, Rambod E. A wearable HD device for patients with end-stage renal failure: a pilot study. Lancet. 2007;370:2005-10.
Gura V, Davenport A, Beizai M, Ezon C, Ronco C. Beta2-microglobulin and phosphate clearances using a wearable artificial kidney: a pilot study. Am J Kidney Dis. 2009;54:104-11.
Foo MWY, Htay H, Gow S, Mandar G, Yajaballa M, Huda SN, et al. Effect of automated wearable artificical kidney (AWAK) device on toxin clearance and safety in peritoneal dialysis patients. Am Soc Nephrol. 2019. Washington DC abstract FR-OR101. Available from: asn-online.org/abstracts
Gura V, Rivara MB, Bieber S, Munshi R, Smith NC, Linke L, et al. A wearable artificial kidney for patients with end-stage renal disease. JCI Insight. 2016;1:e86397.